Turning Point Therapeutics to Participate in H.C. Wainwright Precision Oncology Investor Conference


SAN DIEGO, Sept. 21, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced that President and CEO Athena Countouriotis, M.D., will participate in two question and answer sessions at the H.C. Wainwright Virtual Precision Oncology Conference on Sept. 24.

View post:
Turning Point Therapeutics to Participate in H.C. Wainwright Precision Oncology Investor Conference

Related Posts